BCRX
BIOCRYST PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$8.07
+3.59%Year over year
Reported trailing growth
- Revenue
- +68.7%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +2165.8%
- Operating cash flow
- +2039.9%
Forward estimates
Based on analyst estimates
- Revenue
- -23.2%
- EBITDA
- +195.1%
- EPS
- +143.8%
Three-year CAGR
- Revenue
- +47.8%
- EBITDA
- +2614.3%
- EBIT
- —
- Net income
- +396.9%
- EPS
- +393.0%
- Free cash flow
- +716.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026